Effects of age, gender, and immunosuppressive agents on in vivo toll-like receptor pathway responses

Effects of age, gender, and immunosuppressive agents on in vivo toll-like receptor pathway responses
复制标题

DOI:
10.1016/j.humimm.2010.01.018
复制
发表时间:
2010-04-01
期刊:
影响因子:
2.7
通讯作者:
Arkwright, Peter D.
Arkwright, Peter D.
中科院分区:
医学4区
文献类型:
--
作者:
Khan, Niamat;Summers, Colin W.;Arkwright, Peter D.

文献摘要

被引文献

相似文献

toll样受体(TLRs)在健康和疾病的免疫反应启动中都很重要。TLR活性如何随年龄、性别以及免疫抑制剂而改变,在很大程度上仍未被探索。我们研究了49名健康人以及26名接受免疫抑制药物治疗的患者的TLR活性。在2岁到67岁之间,TLR活性没有显著改变。然而,雌性的TLR7配体诱导的干扰素-1应答是雄性的两倍(OR [95% CI] 2.7[1.4-5.1]),而TLR3和四种活性在两性之间没有显著差异。t细胞免疫抑制剂环孢素、他克莫司和硫唑嘌呤以及低剂量糖皮质激素没有显著改变TLR通路反应。相比之下,高剂量糖皮质激素使体内TLR反应降低了70%-90%。我们认为TLR反应的性别差异可能有助于解释某些自身免疫性疾病的女性优势。此外,了解免疫抑制剂对tlr通路活性的影响,可以使自身免疫性疾病的治疗更加集中。(C) 2010年美国组织相容性和免疫遗传学学会。Elsevier Inc.出版。版权所有。
Toll-like receptors (TLRs) are important in the initiation of immune responses in both health and disease. How TLR activity alters with age, gender, and also with immunosuppressive agents is still largely unexplored. We studied TLR activity in 49 healthy individuals as well as in 26 patients receiving immunosuppressive drugs. TLR activity did not alter significantly between the ages of 2 and 67 years. However, females had twice the TLR7 ligand-induced interferon-1 response of males (OR [95% CI] 2.7 [1.4-5.1]), whereas TLR3 and four activities were not significantly different between the sexes. The T-cell immunosuppressant agents cyclosporine, tacrolimus, and azathioprine, as well as low dose glucocorticosteroids did not significantly alter TLR pathway responses. In contrast, high dose glucocorticosteroids reduced in vivo TLR responses by 70%-90%. We suggest that gender differences in TLR responses may help to explain the female preponderance of some autoimmune disorders. Furthermore, an understanding the effects of immunosuppressive agents on TLR-pathway activity should allow more focused therapy for autoimmune disorders. (C) 2010 American Society for Histocompatibility and Immunogenetics. Published by Elsevier Inc. All rights reserved.